查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2103687

神經退化性疾病治療市場：全球市場預測，2026-2032年

Neurodegenerative Drugs Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，神經退化性疾病治療市場規模將成長至 815.1 億美元，複合年成長率為 7.92%。

主要市場統計數據
基準年 2025 477.9億美元
預計年份：2026年 513.9億美元
預測年份 2032 815.1億美元
複合年成長率 (%) 7.92%

神經退化性疾病藥物的引入

隨著疾病負擔日益加重、人口老化、診斷途徑的改進以及疾病生物學的進展，神經退化性疾病疾病的治療正處於關鍵時刻，這些因素正在重塑阿茲海默症、帕金森氏症、肌萎縮側索硬化症（ALS）、亨廷頓舞蹈症、與多發性硬化症相關的神經退化疾病以及罕見遺傳性神經系統疾病的治療重點。世界衛生組織（WHO）意識到，神經系統疾病是全球殘疾的主要原因之一，而各國的老化和腦部健康策略也日益重視失智症和帕金森氏症。在這一領域，治療策略正從主要針對症狀的治療轉向以緩解疾病為標靶的治療策略，這些策略旨在改善澱粉樣蛋白、 Tau蛋白、α-突觸核蛋白、神經發炎、粒線體功能障礙、溶酶體路徑、突觸喪失和遺傳因素等。監管機構越來越重視基於生物標記的開發、真實世界數據、以患者為中心的終點以及批准後的監測，這反映了旨在改變疾病進程的療法的潛力和複雜性。

神經退化性疾病治療領域的變革性變化

神經退化性疾病治療領域正經歷著一場變革，精準神經病學、基於生物標記定義的患者群體以及基於機制的治療設計正成為主流。在阿茲海默症的研究和開發中，抗澱粉樣蛋白和抗Tau蛋白療法的研究興趣日益濃厚；而帕金森氏症的研究計畫則越來越關注α-突觸核蛋白聚集、Glucocerebrosidase脂酶相關生物學、神經發炎以及多巴胺能神經保護。在肌萎縮側索硬化症（ALS）和罕見神經遺傳性疾病中，反義寡核苷酸、基因標靶治療、RNA調控以及突變特異性療法正透過將治療選擇與分子診斷結合，重塑臨床策略。

人工智慧對神經退化性疾病治療的累積影響

人工智慧正在對神經退化性疾病的藥物發現、臨床開發、診斷和治療監測等各個領域產生累積影響。在研究早期階段，人工智慧平台透過分析基因組學、蛋白質組學、轉錄組學、影像學、病理學和縱向臨床資料集，輔助標靶識別。機器學習模型有助於優先識別與蛋白質錯誤折疊、神經發炎、突觸功能障礙和神經元喪失相關的分子路徑。同時，計算化學和生成模型正被用於化合物篩檢、結合特性最佳化以及提高藥物在中樞神經系統的適用性。

全球神經退化性疾病治療所引入的關鍵區域性見解

在亞太地區，人口快速老化、神經系統基礎設施的不斷完善以及對失智症和運動障礙護理投入的增加，正在影響著神經退化性疾病治療的發展。日本、中國、韓國、印度和澳洲在該地區的發展中發揮核心作用，這些國家擴大使用生物標記診斷技術，積極參與臨床試驗，並在失智症護理的公共衛生舉措取得了進展。日本的超老齡化社會對阿茲海默症和帕金森氏症的治療路徑提出了強勁的需求，而中國龐大的患者群體和不斷擴展的醫院科研網路則為更廣泛的臨床開發提供了支持。在印度，神經系統疾病的診療服務正在改善，但診斷差異、經濟負擔和專科醫生分佈不均等挑戰仍然存在。

針對特定群體的關鍵見解，有助於確定神經退化性疾病治療的優先事項

在東南亞國協，健康老化、提高失智症以及加強非傳染性疾病防治能力的重要性日益凸顯，但神經退化性疾病的治療現狀仍然差異巨大。新加坡和泰國擁有相對完善的神經科專科服務和研究基礎設施，但包括印尼、越南和菲律賓在內的其他東協成員國則面臨更嚴峻的就醫障礙，例如專科醫生數量不足、診斷資源匱乏以及自付費用高昂等。該地區的進展取決於可擴展的認知篩檢、轉診途徑以及減輕經濟負擔的框架。

各國在神經退化性疾病治療的研發和普及方面的關鍵見解。

美國憑藉其先進的臨床試驗網路、生物標記基礎設施、患者登記系統以及支持加速核准流程的監管機制，在神經退化性疾病治療研發領域發揮核心促進者，尤其針對那些存在未滿足醫療需求的嚴重。阿茲海默症修飾療法的引入凸顯了早期診斷、澱粉樣蛋白識別、MRI監測、靜脈給藥系統以及保險公司提供的證據要求的重要性。在加拿大，國家失智症計畫、學術神經學調查和協作醫療受到重視，但患者獲得醫療服務的決策受到公共保險報銷流程和省級醫療體系的影響。在墨西哥，儘管對失智症和帕金森氏症治療的需求不斷成長，但獲得專科醫生、影像診斷和成本效益等方面的可及性仍然影響著患者的治療路徑。

為神經退化性疾病治療行業的領導者提供的實用建議

產業領導者應從研究早期階段就優先考慮以生物標記為導向的開發策略，協調目標生物學機制、患者選擇、終點設計和監管預期。對於阿茲海默症和帕金森氏症，這意味著在科學適用的情況下整合檢驗的影像學、體液生物標記、遺傳標記和數位化測量。對於肌萎縮側索硬化症（ALS）、亨廷頓舞蹈症和罕見神經遺傳性疾病，突變特異性篩檢、自然史資料集以及與患者登記機構的合作應在臨床試驗準備工作中發揮核心作用。

基於證據的神經退化性疾病治療分析的調查方法

一套完善的神經退化性疾病治療調查方法應結合一手和二手研究、臨床證據審查、監管分析以及醫療基礎設施評估。二手研究應包括同行評審的醫學文獻、臨床試驗註冊資訊、監管文件、治療指南、衛生技術評估報告、藥物安全監測資訊、流行病學數據和公共衛生政策出版物。一手研究可能包括與神經科醫生、老年病學家、精神科醫生、放射科醫生、臨床檢驗醫師、保險公司、臨床試驗研究人員、患者權益組織代表和醫療機構管理人員進行系統性討論。

結論：促進神經退化性疾病。

神經退化性疾病的治療正從以症狀為中心的管理轉向以生物標記為依據的標靶治療，並有可能緩解疾病進程。蛋白質聚集、神經發炎、遺傳學、突觸生物學和數位表現型分析等領域的科學進步正在拓展治療機會，而人工智慧在改善藥物發現、臨床試驗設計、診斷和實際監測方面發揮著重要作用。然而，該領域的成功並非僅取決於治療效果。它還需要可靠的早期診斷、公平獲取生物標記的機會、訓練有素的專業人員網路、保險公司的信任、對看護者的支持以及嚴格的長期安全監測。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：神經退化性疾病治療市場：依藥物類型分類

  • 膽鹼酯酶抑制劑
    • 多奈哌齊
    • 吡啶斯的明
    • Rivastigmine
  • 脫羧酶抑制劑
    • 芐絲肼
    • 碳度巴
    • 甲基多巴
  • 多巴胺促效劑
    • 阿撲嗎啡
    • 卡麥角林
    • Pramipexole
    • rotigotine
  • 免疫調節劑

第8章：神經退化性疾病治療市場：依給藥途徑分類

  • 注射藥物
  • 口服
  • 經皮吸收貼片

第9章：神經退化性疾病治療市場：依作用機制分類

  • 離子通道調節劑
    • 鉀通道調變器
    • 鈉通道調變器
  • 突觸調變器

第10章：神經退化性疾病治療市場：依治療類型分類

  • 神經保護
    • 抗發炎藥
    • 抗氧化劑
  • 預防性治療
  • 症狀治療

第11章：神經退化性疾病治療市場：依適應症類型分類

  • 阿茲海默症
  • 肌萎縮側索硬化症（ALS）
  • 多發性硬化症
    • 原發性進行性
    • 復發緩解型
  • 帕金森氏症

第12章：神經退化性疾病治療市場：依銷售管道分類

  • 離線
    • 醫院藥房
    • 零售藥房
  • 線上

第13章：神經退化性疾病治療市場：依最終用戶分類

  • 診所
  • 受託研究機構
  • 醫院
  • 研究機構

第14章：神經退化性疾病治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第15章：神經退化性疾病治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：神經退化性疾病治療市場：依國家分類

  • 美國
  • 德國
  • 中國
  • 英國
  • 印度
  • 日本
  • 俄羅斯
  • 巴西
  • 加拿大
  • 義大利
  • 墨西哥
  • 法國
  • 西班牙
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第18章：公司簡介

  • AbbVie Inc
  • AC Immune SA
  • Acadia Pharmaceuticals Inc
  • Alnylam Pharmaceuticals Inc
  • Alzheon Inc
  • Amneal Pharmaceuticals Inc
  • Amylyx Pharmaceuticals Inc
  • AstraZeneca PLC
  • Bayer AG
  • BioArctic AB
  • Biogen Inc
  • Bristol Myers Squibb Co
  • Cassava Sciences Inc
  • Denali Therapeutics Inc
  • Eisai Co Ltd
  • Eli Lilly and Company
  • Ionis Pharmaceuticals Inc
  • Lundbeck AS
  • Merck Co Inc
  • Neuren Pharmaceuticals
  • Neurocrine Biosciences Inc
  • Novartis AG
  • Orion Pharma
  • Pfizer Inc
  • Sage Therapeutics Inc
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd
  • UCB SA
  • Voyager Therapeutics Inc
Product Code: MRR-C002B1C996F9

The Neurodegenerative Drugs Market is projected to grow by USD 81.51 billion at a CAGR of 7.92% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 47.79 billion
Estimated Year [2026] USD 51.39 billion
Forecast Year [2032] USD 81.51 billion
CAGR (%) 7.92%

Executive Introduction to Neurodegenerative Drugs

Neurodegenerative drugs are entering a pivotal phase as rising disease burden, aging populations, improved diagnostic pathways, and advances in disease biology reshape therapeutic priorities across Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, multiple sclerosis-related neurodegeneration, and rare inherited neurological disorders. The World Health Organization recognizes neurological disorders as a major contributor to disability worldwide, while dementia and Parkinson's disease are increasingly prioritized in national aging and brain health strategies. The sector is shifting from predominantly symptomatic treatment toward disease-modifying strategies that target amyloid, tau, alpha-synuclein, neuroinflammation, mitochondrial dysfunction, lysosomal pathways, synaptic loss, and genetic drivers. Regulatory agencies have increasingly emphasized biomarker-supported development, real-world evidence, patient-centered endpoints, and post-approval monitoring, reflecting both the promise and complexity of therapies intended to alter disease trajectories.

Clinical and commercial momentum is being shaped by the need for earlier diagnosis, scalable biomarker testing, equitable access to specialty care, and robust pharmacovigilance. Cerebrospinal fluid assays, amyloid and tau PET imaging, plasma-based biomarkers, digital cognitive assessments, and genetic testing are helping identify patients earlier and refine trial enrollment. At the same time, safety monitoring requirements, infusion capacity, payer scrutiny, and caregiver burden remain critical adoption barriers. For stakeholders across pharmaceutical development, healthcare delivery, reimbursement, and public health, neurodegenerative drugs represent a high-priority therapeutic field where scientific progress must be matched by operational readiness and evidence generation.

Transformative Shifts in the Neurodegenerative Drugs Landscape

The neurodegenerative drugs landscape is being transformed by a move toward precision neurology, biomarker-defined populations, and mechanism-based treatment design. Alzheimer's disease development has accelerated interest in anti-amyloid and anti-tau approaches, while Parkinson's disease programs increasingly investigate alpha-synuclein aggregation, glucocerebrosidase-related biology, neuroinflammation, and dopaminergic neuroprotection. In ALS and rare neurogenetic disorders, antisense oligonucleotides, gene-targeted therapies, RNA modulation, and mutation-specific approaches are reshaping clinical strategy by linking treatment selection to molecular diagnosis.

Another major shift is the expansion of trial endpoints beyond traditional clinical scales. Sponsors and investigators are increasingly incorporating fluid biomarkers, imaging outcomes, digital motor measures, speech analytics, wearables, remote cognitive testing, and patient-reported outcomes to detect progression earlier and reduce variability. Decentralized and hybrid trial models are also gaining importance because neurodegenerative diseases often limit patient mobility and impose substantial caregiver demands. Meanwhile, regulatory frameworks are evolving to balance accelerated access with evidence requirements, especially where biomarker changes are considered reasonably likely to predict clinical benefit.

Healthcare systems are also undergoing structural change. Disease-modifying therapies often require early diagnosis, specialist confirmation, baseline imaging or laboratory assessment, infusion or complex administration pathways, and longitudinal safety surveillance. This is driving greater integration among neurologists, memory clinics, radiology networks, genetic counselors, primary care providers, specialty pharmacies, and patient advocacy organizations. The most successful ecosystem participants are those aligning scientific innovation with diagnosis capacity, reimbursement evidence, treatment monitoring, and equitable patient navigation.

Cumulative Impact of Artificial Intelligence on Neurodegenerative Drugs

Artificial intelligence is becoming a cumulative force across neurodegenerative drug discovery, clinical development, diagnosis, and treatment monitoring. In early research, AI-enabled platforms support target identification by analyzing genomics, proteomics, transcriptomics, imaging, pathology, and longitudinal clinical datasets. Machine learning models can help prioritize molecular pathways involved in protein misfolding, neuroinflammation, synaptic dysfunction, and neuronal loss, while computational chemistry and generative modeling are being used to screen compounds, optimize binding properties, and improve central nervous system drug-likeness.

In clinical development, AI is strengthening patient stratification and trial design. Algorithms that integrate electronic health records, biomarker results, imaging features, speech patterns, gait metrics, and cognitive data can help identify participants at defined disease stages and reduce heterogeneity. AI-supported imaging analysis is improving quantification of brain atrophy, amyloid and tau burden, dopaminergic pathway changes, and white matter integrity. Digital phenotyping through smartphones and wearables is also enabling more continuous measurement of tremor, bradykinesia, gait, sleep disruption, speech changes, and cognitive fluctuation, potentially reducing reliance on infrequent clinic-based assessments.

The cumulative impact of AI also extends to post-approval safety, adherence, and real-world evidence. Neurodegenerative drugs may carry complex monitoring needs, including imaging surveillance, laboratory testing, drug interaction assessment, and adverse event detection. AI-enabled pharmacovigilance can identify safety signals across claims, registries, clinical notes, and patient-reported data when appropriate governance is in place. However, adoption depends on validated models, transparent performance metrics, representative datasets, privacy safeguards, clinical oversight, and regulatory acceptance. AI is not replacing clinical judgment in neurology; it is increasingly functioning as an evidence accelerator that improves precision, efficiency, and continuity of care.

Key Regional Insights Across Global Neurodegenerative Drug Adoption

In Asia-Pacific, neurodegenerative drug activity is influenced by rapid population aging, expanding neurology infrastructure, and growing investment in dementia and movement disorder care. Japan, China, South Korea, India, and Australia are central to regional progress, with increasing use of biomarker diagnostics, clinical trial participation, and public health initiatives addressing dementia. Japan's super-aged population has created strong demand for Alzheimer's and Parkinson's disease care pathways, while China's large patient base and expanding hospital research networks are supporting broader clinical development. India is strengthening neurological care access but continues to face diagnostic gaps, affordability constraints, and uneven specialty distribution.

North America remains a leading region for neurodegenerative drug innovation due to established clinical trial networks, advanced imaging and biomarker capabilities, specialized neurology centers, and mature regulatory pathways for expedited review where serious unmet need exists. The United States has been central to Alzheimer's disease-modifying therapy implementation, real-world evidence generation, and biomarker-guided treatment decisions, while Canada contributes through academic research networks, universal care frameworks, and increasing focus on dementia strategies and rare neurological disorders.

Latin America is characterized by rising recognition of dementia, Parkinson's disease, and other neurodegenerative conditions, alongside persistent disparities in specialist access and advanced diagnostics. Brazil and Mexico are particularly important due to their large populations, growing clinical research participation, and public health interest in aging-related neurological disorders. Access to high-complexity biologics, genetic testing, PET imaging, and specialized infusion services remains uneven, making affordability and healthcare infrastructure decisive factors for therapy uptake.

Europe benefits from strong neurological research institutions, cross-border scientific collaboration, national dementia plans, health technology assessment systems, and established pharmacovigilance infrastructure. Western European countries tend to have broader access to specialized diagnostics and multidisciplinary neurology care, while parts of Central and Eastern Europe face more constrained access to advanced imaging, biomarker testing, and innovative therapies. European systems place strong emphasis on comparative effectiveness, safety monitoring, and cost-effectiveness evidence before broad reimbursement.

The Middle East is advancing through investments in specialty hospitals, genomic medicine, and tertiary care services, particularly in Gulf countries. Rising awareness of dementia and Parkinson's disease is increasing demand for neurology services, although access varies widely across the region. Genetic counseling and consanguinity-related rare neurological disease considerations are particularly relevant in some populations, supporting interest in precision medicine and inherited neurodegenerative disorder diagnostics.

Africa faces a growing but underdiagnosed neurodegenerative disease burden as life expectancy rises and noncommunicable disease surveillance improves. Many countries experience shortages of neurologists, limited access to neuroimaging, restricted biomarker testing, and low public awareness of dementia and movement disorders. However, regional progress in academic neurology, community health models, and global research collaborations is creating opportunities to improve diagnosis, registry development, and equitable access to essential neurological medicines.

Key Group Insights Shaping Neurodegenerative Drug Priorities

ASEAN countries are increasingly prioritizing healthy aging, dementia awareness, and noncommunicable disease capacity building, but the neurodegenerative drugs environment remains highly diverse. Singapore and Thailand have comparatively more developed specialty neurology services and research infrastructure, while Indonesia, Vietnam, the Philippines, and other ASEAN members face greater access barriers related to specialist density, diagnostic availability, and out-of-pocket costs. Regional progress depends on scalable cognitive screening, referral pathways, and affordability frameworks.

The GCC is strengthening its position through investment in advanced hospitals, genomic screening initiatives, digital health infrastructure, and specialty care hubs. Neurodegenerative drug access is supported by high healthcare spending in several member states, but long-term adoption depends on building memory clinics, movement disorder programs, trained neurologists, imaging capacity, and pharmacovigilance systems. The GCC's interest in precision medicine is especially relevant for rare inherited neurodegenerative conditions and population-specific genetic research.

The European Union provides a highly structured environment for neurodegenerative drug assessment through centralized regulatory review, national reimbursement decisions, health technology assessment coordination, and strong post-marketing safety systems. EU countries support extensive research in Alzheimer's disease, Parkinson's disease, ALS, multiple sclerosis-related neurodegeneration, and rare neurological disorders. However, differences in national reimbursement, diagnostic capacity, and specialist access can create variation in the timing and breadth of patient access after authorization.

BRICS economies represent a major strategic grouping due to large patient populations, expanding biomedical research capabilities, and growing government attention to aging and chronic disease. China and India are particularly influential because of demographic scale and increasing clinical trial activity, while Brazil and South Africa play important roles in regional access and research development. Russia maintains scientific and clinical interest in neurology, though broader geopolitical and regulatory factors can affect collaboration and medicine availability.

G7 countries have substantial influence on neurodegenerative drug development because they combine advanced research ecosystems, regulatory experience, high diagnostic sophistication, and major public funding for neurological disease research. The United States, Japan, Germany, France, the United Kingdom, Italy, and Canada are central to evidence generation, clinical guideline development, and reimbursement debate. Their policy decisions often shape global expectations for biomarker validation, clinical meaningfulness, safety management, and real-world data requirements.

NATO member countries collectively include many high-income healthcare systems with advanced neurology capabilities, but the grouping is not primarily a health policy bloc. Within NATO countries, neurodegenerative drug adoption is shaped by national regulatory alignment, reimbursement frameworks, defense-related brain health research, veteran neurological care, and cross-border scientific collaboration. Traumatic brain injury, neuropsychiatric comorbidity, and long-term neurological monitoring in military and veteran populations can add specific relevance to neurodegeneration research priorities.

Key Country Insights for Neurodegenerative Drug Development and Access

The United States is a core driver of neurodegenerative drug development through advanced clinical trial networks, biomarker infrastructure, patient registries, and regulatory mechanisms that support expedited pathways for serious diseases with unmet need. Implementation of disease-modifying Alzheimer's therapies has highlighted the importance of early diagnosis, amyloid confirmation, MRI monitoring, infusion capacity, and payer evidence requirements. Canada emphasizes national dementia planning, academic neurology research, and coordinated care, while access decisions are shaped by public reimbursement processes and provincial healthcare structures. Mexico is seeing rising demand for dementia and Parkinson's disease care, although specialist availability, diagnostic imaging access, and affordability continue to influence patient pathways.

Brazil is a major Latin American hub for neurological research and clinical care, with increasing attention to dementia, Parkinson's disease, ALS, and multiple sclerosis. Public and private sector differences affect access to advanced therapies and diagnostics. The United Kingdom benefits from strong neuroscience research, dementia policy initiatives, genetic medicine programs, and structured health technology assessment, making clinical effectiveness and value evidence central to adoption. Germany has extensive neurology infrastructure, advanced diagnostics, and strong clinical research capabilities, while France combines national health coverage, neuroscience research networks, and growing emphasis on early dementia diagnosis. Russia has a substantial neurology patient base and clinical expertise, but access to advanced neurodegenerative therapies can be affected by regulatory, procurement, and geopolitical factors. Italy and Spain have strong academic neurology communities, aging populations, and active dementia and movement disorder care pathways, though regional healthcare variation can influence diagnostic and treatment access.

China is expanding rapidly in neurodegenerative disease research, clinical trial capacity, hospital-based specialty care, and biomarker adoption, supported by the country's large aging population and increasing focus on brain health. India has a substantial unmet need in dementia, Parkinson's disease, and motor neuron disease care, with opportunities centered on low-cost diagnostics, tele-neurology, physician education, and broader access to essential and advanced medicines. Japan is among the most important countries for neurodegenerative drugs because of its advanced aging profile, established neurology expertise, and strong focus on Alzheimer's disease, Parkinson's disease, and regenerative medicine research. Australia contributes through high-quality clinical research, dementia care frameworks, and population health initiatives, with geography making telehealth and distributed care models important. South Korea is advancing through biomedical innovation, digital health capabilities, aging-related healthcare investment, and increasing clinical research participation in central nervous system disorders.

Actionable Recommendations for Neurodegenerative Drug Industry Leaders

Industry leaders should prioritize biomarker-enabled development strategies that align target biology, patient selection, endpoint design, and regulatory expectations from the earliest stages of research. For Alzheimer's disease and Parkinson's disease, this means integrating validated imaging, fluid biomarkers, genetic markers, and digital measures where scientifically appropriate. For ALS, Huntington's disease, and rare neurogenetic disorders, mutation-specific screening, natural history datasets, and patient registry partnerships should be central to trial readiness.

Organizations should also invest in access infrastructure before product launch. Disease-modifying neurodegenerative therapies often require diagnostic confirmation, specialist consultation, infusion or complex administration, safety imaging, laboratory monitoring, and caregiver support. Early collaboration with neurologists, radiologists, laboratory networks, payers, patient organizations, and health systems can reduce bottlenecks and support responsible adoption. Evidence packages should include clinical outcomes, biomarker rationale, quality-of-life measures, caregiver burden data, health resource utilization, and real-world safety plans.

To strengthen competitive positioning without relying on promotional claims, leaders should focus on transparent evidence generation, inclusive trial enrollment, decentralized participation options, and long-term pharmacovigilance. AI and digital health tools should be implemented with validation, bias assessment, data security, and clinician oversight. Finally, developers and healthcare stakeholders should prepare differentiated strategies for high-income markets, emerging economies, and under-resourced settings, recognizing that diagnosis capacity and affordability are as important as therapeutic innovation.

Research Methodology for Evidence-Based Neurodegenerative Drug Analysis

A robust research methodology for neurodegenerative drugs should combine primary and secondary research, clinical evidence review, regulatory analysis, and healthcare infrastructure assessment. Secondary research includes peer-reviewed medical literature, clinical trial registries, regulatory agency documents, treatment guidelines, health technology assessment reports, pharmacovigilance communications, epidemiological sources, and public health policy publications. Primary research may include structured discussions with neurologists, geriatricians, psychiatrists, radiologists, laboratory medicine specialists, payers, clinical trial investigators, patient advocacy representatives, and healthcare administrators.

The methodology should evaluate drug classes and mechanisms across symptomatic therapies, disease-modifying biologics, small molecules, RNA-based therapies, gene-targeted approaches, neuroprotective agents, and supportive treatments. It should also assess disease areas including Alzheimer's disease, Parkinson's disease, ALS, Huntington's disease, multiple sclerosis-associated neurodegeneration, frontotemporal dementia, and rare inherited disorders. Key evidence dimensions include mechanism of action, clinical trial phase and design, biomarker use, endpoint selection, safety profile, administration requirements, monitoring burden, real-world evidence, regulatory status, and access considerations.

Data validation should rely on triangulation across clinical publications, regulatory filings, expert input, and healthcare system evidence. Because this field evolves rapidly, methodology must include systematic update protocols for trial readouts, label changes, safety warnings, diagnostic guideline updates, and reimbursement decisions. Strict separation between verified evidence and assumptions is essential, and analysis should avoid unsupported projections, promotional interpretation, or unverified commercial claims.

Conclusion: Advancing Evidence-Led Neurodegenerative Drug Innovation

Neurodegenerative drugs are progressing from symptom-focused management toward targeted, biomarker-supported, and potentially disease-modifying care. Scientific advances in protein aggregation, neuroinflammation, genetics, synaptic biology, and digital phenotyping are expanding therapeutic opportunities, while AI is improving discovery, trial design, diagnosis, and real-world monitoring. However, the field's success depends on more than therapeutic efficacy alone; it requires reliable early diagnosis, equitable biomarker access, trained specialist networks, payer confidence, caregiver support, and rigorous long-term safety surveillance.

Regional and country-level differences in neurology infrastructure, reimbursement, diagnostic capacity, and public health priorities will strongly influence how neurodegenerative drugs reach patients. High-income markets are likely to lead in complex therapy implementation, while emerging regions require scalable models that address affordability and specialist shortages. Industry leaders that combine scientific rigor with operational readiness, inclusive evidence generation, and responsible AI adoption will be best positioned to improve outcomes in Alzheimer's disease, Parkinson's disease, ALS, Huntington's disease, and other debilitating neurological disorders.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Neurodegenerative Drugs Market, by Drug Type

  • 7.1. Introduction
  • 7.2. Cholinesterase Inhibitors
    • 7.2.1. Donepezil
    • 7.2.2. Pyridostigmine
    • 7.2.3. Rivastigmine
  • 7.3. Decarboxylase Inhibitors
    • 7.3.1. Benserazide
    • 7.3.2. Carbidopa
    • 7.3.3. Methyldopa
  • 7.4. Dopamine Agonist
    • 7.4.1. Apomorphine
    • 7.4.2. Cabergoline
    • 7.4.3. Pramipexole
    • 7.4.4. Rotigotine
  • 7.5. Immunomodulators

8. Neurodegenerative Drugs Market, by Mode Of Administration

  • 8.1. Introduction
  • 8.2. Injectable
  • 8.3. Oral
  • 8.4. Transdermal Patch

9. Neurodegenerative Drugs Market, by Mechanism Of Action

  • 9.1. Introduction
  • 9.2. Ion Channel Modulators
    • 9.2.1. Potassium Channel Modulators
    • 9.2.2. Sodium Channel Modulators
  • 9.3. Synaptic Modulators

10. Neurodegenerative Drugs Market, by Therapeutic Type

  • 10.1. Introduction
  • 10.2. Neuroprotection
    • 10.2.1. Anti-Inflammatory Agents
    • 10.2.2. Antioxidants
  • 10.3. Preventive Treatment
  • 10.4. Symptomatic Treatment

11. Neurodegenerative Drugs Market, by Indication Type

  • 11.1. Introduction
  • 11.2. Alzheimer's Disease
  • 11.3. Amyotrophic Lateral Sclerosis (ALS)
  • 11.4. Multiple Sclerosis
    • 11.4.1. Primary Progressive
    • 11.4.2. Relapsing-Remitting
  • 11.5. Parkinson's Disease

12. Neurodegenerative Drugs Market, by Sales Channel

  • 12.1. Introduction
  • 12.2. Offline
    • 12.2.1. Hospitals Pharmacies
    • 12.2.2. Retail Pharmacies
  • 12.3. Online

13. Neurodegenerative Drugs Market, by End User

  • 13.1. Introduction
  • 13.2. Clinics
  • 13.3. Contract Research Organizations
  • 13.4. Hospitals
  • 13.5. Research Institutes

14. Neurodegenerative Drugs Market, by Region

  • 14.1. Asia-Pacific
  • 14.2. North America
  • 14.3. Latin America
  • 14.4. Europe
  • 14.5. Middle East
  • 14.6. Africa

15. Neurodegenerative Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Neurodegenerative Drugs Market, by Country

  • 16.1. United States
  • 16.2. Germany
  • 16.3. China
  • 16.4. United Kingdom
  • 16.5. India
  • 16.6. Japan
  • 16.7. Russia
  • 16.8. Brazil
  • 16.9. Canada
  • 16.10. Italy
  • 16.11. Mexico
  • 16.12. France
  • 16.13. Spain
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2025
  • 17.2. FPNV Positioning Matrix, 2025
  • 17.3. Market Concentration Analysis, 2025
    • 17.3.1. Concentration Ratio (CR)
    • 17.3.2. Herfindahl Hirschman Index (HHI)
  • 17.4. Recent Developments & Impact Analysis, 2025
  • 17.5. Product Portfolio Analysis, 2025
  • 17.6. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. AbbVie Inc
  • 18.2. AC Immune SA
  • 18.3. Acadia Pharmaceuticals Inc
  • 18.4. Alnylam Pharmaceuticals Inc
  • 18.5. Alzheon Inc
  • 18.6. Amneal Pharmaceuticals Inc
  • 18.7. Amylyx Pharmaceuticals Inc
  • 18.8. AstraZeneca PLC
  • 18.9. Bayer AG
  • 18.10. BioArctic AB
  • 18.11. Biogen Inc
  • 18.12. Bristol Myers Squibb Co
  • 18.13. Cassava Sciences Inc
  • 18.14. Denali Therapeutics Inc
  • 18.15. Eisai Co Ltd
  • 18.16. Eli Lilly and Company
  • 18.17. Ionis Pharmaceuticals Inc
  • 18.18. Lundbeck AS
  • 18.19. Merck Co Inc
  • 18.20. Neuren Pharmaceuticals
  • 18.21. Neurocrine Biosciences Inc
  • 18.22. Novartis AG
  • 18.23. Orion Pharma
  • 18.24. Pfizer Inc
  • 18.25. Sage Therapeutics Inc
  • 18.26. Sanofi SA
  • 18.27. Takeda Pharmaceutical Company Limited
  • 18.28. Teva Pharmaceutical Industries Ltd
  • 18.29. UCB SA
  • 18.30. Voyager Therapeutics Inc

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEURODEGENERATIVE DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL NEURODEGENERATIVE DRUGS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL NEURODEGENERATIVE DRUGS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL NEURODEGENERATIVE DRUGS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION TYPE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL NEURODEGENERATIVE DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 27. GLOBAL NEURODEGENERATIVE DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL NEURODEGENERATIVE DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CHOLINESTERASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CHOLINESTERASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CHOLINESTERASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DONEPEZIL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DONEPEZIL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DONEPEZIL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PYRIDOSTIGMINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PYRIDOSTIGMINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PYRIDOSTIGMINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL RIVASTIGMINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL RIVASTIGMINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL RIVASTIGMINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DECARBOXYLASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DECARBOXYLASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DECARBOXYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BENSERAZIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BENSERAZIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BENSERAZIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CARBIDOPA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CARBIDOPA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CARBIDOPA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL METHYLDOPA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL METHYLDOPA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL METHYLDOPA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DOPAMINE AGONIST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DOPAMINE AGONIST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DOPAMINE AGONIST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL APOMORPHINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL APOMORPHINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL APOMORPHINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CABERGOLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CABERGOLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CABERGOLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PRAMIPEXOLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PRAMIPEXOLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PRAMIPEXOLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ROTIGOTINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ROTIGOTINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ROTIGOTINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TRANSDERMAL PATCH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TRANSDERMAL PATCH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TRANSDERMAL PATCH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ION CHANNEL MODULATORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ION CHANNEL MODULATORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ION CHANNEL MODULATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL POTASSIUM CHANNEL MODULATORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL POTASSIUM CHANNEL MODULATORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL POTASSIUM CHANNEL MODULATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SODIUM CHANNEL MODULATORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SODIUM CHANNEL MODULATORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SODIUM CHANNEL MODULATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SYNAPTIC MODULATORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SYNAPTIC MODULATORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SYNAPTIC MODULATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NEUROPROTECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEUROPROTECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTI-INFLAMMATORY AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANTI-INFLAMMATORY AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTI-INFLAMMATORY AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANTIOXIDANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTIOXIDANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANTIOXIDANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PREVENTIVE TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PREVENTIVE TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PREVENTIVE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL SYMPTOMATIC TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL SYMPTOMATIC TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL SYMPTOMATIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ALZHEIMER'S DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ALZHEIMER'S DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ALZHEIMER'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS (ALS) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS (ALS) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS (ALS) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PRIMARY PROGRESSIVE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PRIMARY PROGRESSIVE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PRIMARY PROGRESSIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL RELAPSING-REMITTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL RELAPSING-REMITTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL RELAPSING-REMITTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PARKINSON'S DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PARKINSON'S DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL HOSPITALS PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL HOSPITALS PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL HOSPITALS PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. GCC NEURODEGENERATIVE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 238. GCC NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. GCC NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 240. GCC NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 241. GCC NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2032 (USD MILLION)
  • TABLE 242. GCC NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 243. GCC NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 244. GCC NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 245. GCC NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. GCC NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2032 (USD MILLION)
  • TABLE 247. GCC NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. GCC NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
  • TABLE 249. GCC NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 250. GCC NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 251. GCC NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION NEURODEGENERATIVE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS NEURODEGENERATIVE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 282. G7 NEURODEGENERATIVE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 283. G7 NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. G7 NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 285. G7 NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 286. G7 NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2032 (USD MILLION)
  • TABLE 287. G7 NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 288. G7 NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 289. G7 NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 290. G7 NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. G7 NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2032 (USD MILLION)
  • TABLE 292. G7 NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 293. G7 NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
  • TABLE 294. G7 NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 295. G7 NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 296. G7 NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 297. NATO NEURODEGENERATIVE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 298. NATO NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. NATO NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 300. NATO NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 301. NATO NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2032 (USD MILLION)
  • TABLE 302. NATO NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 303. NATO NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 304. NATO NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 305. NATO NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 306. NATO NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2032 (USD MILLION)
  • TABLE 307. NATO NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 308. NATO NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
  • TABLE 309. NATO NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 310. NATO NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 311. NATO NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 312. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 313. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 314. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 315. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 316. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 317. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2032 (USD MILLION)
  • TABLE 318. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 321. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2032 (USD MILLION)
  • TABLE 323. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 324. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
  • TABLE 325. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 326. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 327. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 328. GERMANY NEURODEGENERATIVE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 329. GERMANY NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 330. GERMANY NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 331. GERMANY NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 332. GERMANY NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2032 (USD MILLION)
  • TABLE 333. GERMANY NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 334. GERMANY NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 335. GERMANY NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 336. GERMANY NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2032 (USD MILLION)
  • TABLE 337. GERMANY NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2032 (USD MILLION)
  • TABLE 338. GERMANY NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 339. GERMANY NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
  • TABLE 340. GERMANY NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 341. GERMANY NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 342. GERMANY NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 343. CHINA NEURODEGENERATIVE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 344. CHINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 345. CHINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 346. CHINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 347. CHINA NEURODEGENERAT